推薦產品
product name
星形孢菌素链霉菌sp., InSolution, ≥97%, 1 mM solution, protein kinase inhibitor
品質等級
化驗
≥97% (HPLC)
形狀
liquid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
運輸包裝
wet ice
儲存溫度
−70°C
InChI
1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1
InChI 密鑰
HKSZLNNOFSGOKW-FYTWVXJKSA-N
一般說明
一种有效的、细胞可渗透的广谱蛋白激酶抑制剂。可抑制CaM激酶（IC50 = 20 nM）、肌球蛋白轻链激酶（IC50 = 1.3 nM）、蛋白激酶A（IC50 = 7 nM）、蛋白激酶C（IC50 = 0.7 nM）和蛋白激酶G（IC50 = 8.5 nM）。还可抑制胶原蛋白或ADP诱导的血小板凝集，但对凝血酶诱导的血小板凝集没有影响。诱导人恶性神经胶质瘤细胞系凋亡。在G1检查点对正常细胞进行阻滞。
生化／生理作用
产物与ATP竞争。
可逆性：是
细胞可渗透性：是
靶标IC50：针对蛋白激酶A、CaM激酶、肌球蛋白轻链激酶、蛋白激酶C和蛋白激酶G分别为7 nM、20 nM、1.3 nM、700 pM和8.5 nM。
首要靶标
PKA
PKA
包裝
用惰性气体包装
警告
毒性：刺激性（B）
外觀
1 mM (100 µg/214 µl)星形孢菌素(目录号569397)的DMSO溶液。
重構
初始解冻后，分装，用惰性气体吹扫，然后冻存（-70°C）。
其他說明
Couldwell, W.T., et al. 1994.FEBS Lett.345, 43.
Nishimura, H. and Simpson, I.A.1994.Biochem.J.302, 271.
Bruno, S., et al. 1992.Cancer Res.52, 470.
Kiss, Z. and Deli, E. 1992.Biochem.J.288, 853.
Vitale, M.L., et al. 1992.Neuroscience51, 463.
Hoffman, R. and Newland, E.S.1991.Cancer Chemotherap.Pharmacol.28, 102.
Oka, S., et al. 1986.Agric. Biol. Chem.50, 2723.
Nishimura, H. and Simpson, I.A.1994.Biochem.J.302, 271.
Bruno, S., et al. 1992.Cancer Res.52, 470.
Kiss, Z. and Deli, E. 1992.Biochem.J.288, 853.
Vitale, M.L., et al. 1992.Neuroscience51, 463.
Hoffman, R. and Newland, E.S.1991.Cancer Chemotherap.Pharmacol.28, 102.
Oka, S., et al. 1986.Agric. Biol. Chem.50, 2723.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 1
閃點（°F）
188.6 °F - closed cup - (Dimethylsulfoxide)
閃點（°C）
87 °C - closed cup - (Dimethylsulfoxide)
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Athena Kyrkou et al.
Nature communications, 15(1), 5115-5115 (2024-06-16)
Neurofibromatosis Type II (NFII) is a genetic condition caused by loss of the NF2 gene, resulting in activation of the YAP/TAZ pathway and recurrent Schwann cell tumors, as well as meningiomas and ependymomas. Unfortunately, few pharmacological options are available for
Shuai Guo et al.
British journal of pharmacology, 179(21), 4974-4991 (2022-07-15)
Macrophage-rich atherosclerotic arteries are highly active in glycolysis. PFKFB3, a key glycolytic enzyme, has emerged as a potential therapeutic target in atherosclerosis. Small-molecule inhibitors of PFKFB3, such as 3PO and PFK158, have demonstrated efficacy in hampering atherogenesis in preclinical models.
Erin R Spiller et al.
Frontiers in oncology, 11, 771173-771173 (2022-01-08)
Three-quarters of compounds that enter clinical trials fail to make it to market due to safety or efficacy concerns. This statistic strongly suggests a need for better screening methods that result in improved translatability of compounds during the preclinical testing
Marco Ponzetti et al.
Frontiers in oncology, 12, 983254-983254 (2022-12-23)
Osteosarcoma is the most common primary bone malignancy. The crosstalk between osteosarcoma and the surrounding tumour microenvironment (TME) drives key events that lead to metastasization, one of the main obstacles for definitive cure of most malignancies. Extracellular vesicles (EVs), lipid
Liaisan Arslanbaeva et al.
Redox biology, 51, 102272-102272 (2022-03-08)
Cutaneous melanoma is the deadliest type of skin cancer, although it accounts for a minority of all skin cancers. Oxidative stress is involved in all stages of melanomagenesis and cutaneous melanoma can sustain a much higher load of Reactive Oxygen
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務